Please Wait
Applying Filters...
menu
    • menu
    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Nov 2024: Trump’s HHS pick drags down jab makers’ stocks; Novartis, Merck, Roche ink billion-dollar deals

    Stock Recap
    #PipelineProspector

    Menu

    Zafirlukast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,878Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    30/12/2024 Chromo Laboratories
    India
    		 CHROMO LABORATORIES INDIA PRIVATE LTD 31869 ZAFIRLUKAST 2017-08-18 Active II N/A
    30/12/2024 Chromo Laboratories
    India
    		 CHROMO LABORATORIES INDIA PRIVATE LTD 26359 ZAFIRLUKAST PREMIX-50% W/W 2012-09-28 Active II Complete 2018-12-20 2018-12-18